论文部分内容阅读
据美国风湿病学会会议透露，Ａｍｇｅｎ公司新的类风湿性关节炎治疗药白细胞介素－１受体拮抗剂阿那白滞素（ａｎａｋｉｎｒａ，Ｋｉｎｅｒｅｔ）对减缓关节损害进程，改善生活质量具有开发潜力。 ２０００年１月， Ａｍｇｅｎ公司已在美国提交上市申请，并寻求在加拿大、欧洲
According to a meeting of the American College of Rheumatology, Amgen’s new drug for rheumatoid arthritis, anakinra (Kineret), which is an antagonist of interleukin-1 receptor, has potential for slowing the progression of joint damage and improving the quality of life . January 2000, Amgen Corporation has submitted a listing application in the United States, and seek in Canada, Europe